1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Group A and Group C Meningococcal Polysaccharide Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Group A and Group C Meningococcal Polysaccharide Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Group A and Group C Meningococcal Polysaccharide Vaccine Segment by Type
2.2.1 Class 1 Vaccine
2.2.2 Class II Vaccine
2.3 Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
2.3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Type (2018-2023)
2.4 Group A and Group C Meningococcal Polysaccharide Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
2.5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Application (2018-2023)
3 Global Group A and Group C Meningococcal Polysaccharide Vaccine by Company
3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Breakdown Data by Company
3.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Company (2018-2023)
3.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Company
3.4 Key Manufacturers Group A and Group C Meningococcal Polysaccharide Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Group A and Group C Meningococcal Polysaccharide Vaccine Product Location Distribution
3.4.2 Players Group A and Group C Meningococcal Polysaccharide Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Group A and Group C Meningococcal Polysaccharide Vaccine by Geographic Region
4.1 World Historic Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
4.4 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
4.5 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
4.6 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
5 Americas
5.1 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country
5.1.1 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2023)
5.1.2 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2023)
5.2 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
5.3 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region
6.1.1 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2018-2023)
6.1.2 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2018-2023)
6.2 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
6.3 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine by Country
7.1.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2023)
7.1.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2023)
7.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
7.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine by Country
8.1.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
8.3 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
10.3 Manufacturing Process Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
10.4 Industry Chain Structure of Group A and Group C Meningococcal Polysaccharide Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Group A and Group C Meningococcal Polysaccharide Vaccine Distributors
11.3 Group A and Group C Meningococcal Polysaccharide Vaccine Customer
12 World Forecast Review for Group A and Group C Meningococcal Polysaccharide Vaccine by Geographic Region
12.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size Forecast by Region
12.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Region (2024-2029)
12.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Type
12.7 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Application
13 Key Players Analysis
13.1 Walvax
13.1.1 Walvax Company Information
13.1.2 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.1.3 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Walvax Main Business Overview
13.1.5 Walvax Latest Developments
13.2 Lanzhou Institute of Biological Products
13.2.1 Lanzhou Institute of Biological Products Company Information
13.2.2 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.2.3 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Lanzhou Institute of Biological Products Main Business Overview
13.2.5 Lanzhou Institute of Biological Products Latest Developments
13.3 AIM Bio
13.3.1 AIM Bio Company Information
13.3.2 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.3.3 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 AIM Bio Main Business Overview
13.3.5 AIM Bio Latest Developments
13.4 Sanofi Pasteur
13.4.1 Sanofi Pasteur Company Information
13.4.2 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.4.3 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Sanofi Pasteur Main Business Overview
13.4.5 Sanofi Pasteur Latest Developments
13.5 GSK
13.5.1 GSK Company Information
13.5.2 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.5.3 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 GSK Main Business Overview
13.5.5 GSK Latest Developments
13.6 Hualan Bio
13.6.1 Hualan Bio Company Information
13.6.2 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.6.3 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Hualan Bio Main Business Overview
13.6.5 Hualan Bio Latest Developments
13.7 ZFSW
13.7.1 ZFSW Company Information
13.7.2 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.7.3 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 ZFSW Main Business Overview
13.7.5 ZFSW Latest Developments
13.8 Changsheng
13.8.1 Changsheng Company Information
13.8.2 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.8.3 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Changsheng Main Business Overview
13.8.5 Changsheng Latest Developments
13.9 Kanghua Bio
13.9.1 Kanghua Bio Company Information
13.9.2 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
13.9.3 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Kanghua Bio Main Business Overview
13.9.5 Kanghua Bio Latest Developments
14 Research Findings and Conclusion
※参考情報 グループA及びグループC髄膜炎菌多糖体ワクチンは、髄膜炎菌による感染症予防を目的とするワクチンの一種です。髄膜炎菌は、細菌性髄膜炎や敗血症を引き起こす病原体であり、特に青少年や高齢者において重篤な感染症を引き起こすことがあります。このワクチンは、特にアフリカのサハラ砂漠地域で流行が見られることから、その重要性が高まっています。 このワクチンの基本的な定義としては、A群およびC群の髄膜炎菌由来の多糖体(ポリサッカライド)を用いた予防接種の一環です。多糖体ワクチンは、髄膜炎菌の細胞壁に存在する多糖体を利用し、免疫系に働きかけることで、特定の病原体に対する抗体を生成します。 特徴としては、まず多糖体ワクチンは免疫原性が高く、接種後に迅速に抗体を生成することが挙げられます。通常、接種後数週間で抗体レベルが上昇し、数年間持続することが期待されます。しかしながら、多糖体ワクチンはT細胞依存性ではなく、T細胞応答を伴わないため、成人において比較的短期間の免疫効果しか持たないことがあるのです。そのため、特に若年者や高齢者など、免疫応答が低下している集団には追加接種の必要が生じることがあります。 このワクチンの大きな利点の一つは、多数の感染症による重篤な合併症を防ぐことができる点です。髄膜炎菌による感染症は、迅速に重篤な状態に進行するため早期の予防が不可欠です。このワクチンの接種により、疾患の発生率を大幅に低下させ、最終的に集団免疫を形成することに寄与します。特に、学校や大学の新入生や兵役に就く若者に対しては、ワクチンの接種が奨励されています。 種類としては、現在存在する髄膜炎菌多糖体ワクチンには二種類があり、A群とC群のワクチンです。これらは単独で使用されることもありますが、特にグループAとグループCを組み合わせたワクチンも開発されており、同時に複数の感染症に対応することができます。近年では、より長期的な免疫を提供するために、タンパク質と結合させたコンジュゲートワクチンの開発も進められており、これにより特に小児や若年層における免疫効果が向上しています。 用途については、髄膜炎菌多糖体ワクチンは、特に感染のリスクが高い地域での予防接種プログラムの一環として使用されます。世界保健機関(WHO)などの国際的な健康機関は、高リスク地域での大規模な予防接種キャンペーンを推進しており、これにより流行を抑制する努力がなされています。また、特定のリスクグループ、例えば医療従事者や旅行者、免疫力が低下している患者に対しても接種が推奨されています。 関連技術としては、多糖体ワクチンに加えて、コンジュゲートワクチンやmRNAワクチンなどの新しい技術が進行中です。特にコンジュゲートワクチンは、多糖体とタンパク質を結合させることで、より強力な免疫応答を誘導し、持続的な免疫効果を期待できます。mRNAワクチンは、最近のCOVID-19パンデミックの影響で注目を集め、髄膜炎菌に対する新たなワクチン開発にも応用可能であると考えられています。 髄膜炎菌多糖体ワクチンは、予防接種を通じて感染のリスクを大幅に減少させ、特に発症のリスクが高い集団においては極めて重要な役割を果たしています。このワクチンの導入により、髄膜炎の発生率が顕著に低下した実績もあり、公共の健康に貢献しています。今後も技術革新や新しいワクチンの開発が進むことで、より効果的な予防策が期待されるでしょう。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/